"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
| Descriptor ID |
D000068698
|
| MeSH Number(s) |
D02.705.429.906 D03.633.100.759.138.881
|
| Concept/Terms |
Tenofovir- Tenofovir
- 9-(2-Phosphonylmethoxypropyl)adenine
- 9-PMPA (tenofovir)
- 9-(2-Phosphonomethoxypropyl)adenine
|
Below are MeSH descriptors whose meaning is more general than "Tenofovir".
Below are MeSH descriptors whose meaning is more specific than "Tenofovir".
This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 5 | 5 |
| 2016 | 2 | 3 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 3 | 3 | 6 |
| 2020 | 3 | 3 | 6 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 4 | 5 |
| 2024 | 7 | 10 | 17 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tenofovir" by people in Profiles.
-
Longitudinal Changes in Tenofovir and Tenofovir Diphosphate Concentrations Among Pregnant Women Using Oral PrEP for HIV Prevention: Findings From Durban, South Africa. J Acquir Immune Defic Syndr. 2025 Apr 01; 98(4):357-362.
-
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
-
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025 Jan; 28(1):e26401.
-
Use of tenofovir-based preexposure prophylaxis among pregnant women in South Africa. AIDS. 2025 Apr 01; 39(5):508-518.
-
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort. J Int AIDS Soc. 2024 Dec; 27(12):e26389.
-
Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis. Front Immunol. 2024; 15:1415475.
-
Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV. J Acquir Immune Defic Syndr. 2024 Oct; 97(2):150-155.
-
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.